181 related articles for article (PubMed ID: 30604743)
1. Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists.
Schöppe J; Ehrenmann J; Klenk C; Rucktooa P; Schütz M; Doré AS; Plückthun A
Nat Commun; 2019 Jan; 10(1):17. PubMed ID: 30604743
[TBL] [Abstract][Full Text] [Related]
2. GPCR large-amplitude dynamics by
Pan B; Liu D; Yang L; Wüthrich K
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2122682119. PubMed ID: 35377814
[TBL] [Abstract][Full Text] [Related]
3. Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors.
Halik PK; Lipiński PFJ; Matalińska J; Koźmiński P; Misicka A; Gniazdowska E
Molecules; 2020 Aug; 25(16):. PubMed ID: 32824729
[TBL] [Abstract][Full Text] [Related]
4. NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
Lelas S; Li YW; Wallace-Boone TL; Taber MT; Newton AE; Pieschl RL; Davis CD; Molski TF; Newberry KS; Parker MF; Gillman KW; Bronson JJ; Macor JE; Lodge NJ
Neuropharmacology; 2013 Oct; 73():232-40. PubMed ID: 23770339
[TBL] [Abstract][Full Text] [Related]
5. Illuminating the structural basis of human neurokinin 1 receptor (NK1R) antagonism through classical all-atoms molecular dynamics simulations.
Mishra S; Rout M; Singh MK; Dehury B; Pati S
J Cell Biochem; 2023 Nov; 124(11):1848-1869. PubMed ID: 37942587
[TBL] [Abstract][Full Text] [Related]
6. Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography.
Chen S; Lu M; Liu D; Yang L; Yi C; Ma L; Zhang H; Liu Q; Frimurer TM; Wang MW; Schwartz TW; Stevens RC; Wu B; Wüthrich K; Zhao Q
Nat Commun; 2019 Feb; 10(1):638. PubMed ID: 30733446
[TBL] [Abstract][Full Text] [Related]
7. Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
Wu YJ; He H; Bertekap R; Westphal R; Lelas S; Newton A; Wallace T; Taber M; Davis C; Macor JE; Bronson J
Bioorg Med Chem; 2013 Apr; 21(8):2217-2228. PubMed ID: 23477943
[TBL] [Abstract][Full Text] [Related]
8. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
[TBL] [Abstract][Full Text] [Related]
9. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a cyclopentylamine as an orally active dual NK1 receptor antagonist-serotonin reuptake transporter inhibitor.
Wu YJ; He H; Gao Q; Wu D; Bertekap R; Westphal RS; Lelas S; Newton A; Wallace T; Taber M; Davis C; Macor JE; Bronson J
Bioorg Med Chem Lett; 2014 Mar; 24(6):1611-4. PubMed ID: 24507922
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the human NK
Yin J; Chapman K; Clark LD; Shao Z; Borek D; Xu Q; Wang J; Rosenbaum DM
Proc Natl Acad Sci U S A; 2018 Dec; 115(52):13264-13269. PubMed ID: 30538204
[TBL] [Abstract][Full Text] [Related]
13. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
14. NK1R/5-HT1AR interaction is related to the regulation of melanogenesis.
Wu H; Zhao Y; Huang Q; Cai M; Pan Q; Fu M; An X; Xia Z; Liu M; Jin Y; He L; Shang J
FASEB J; 2018 Jun; 32(6):3193-3214. PubMed ID: 29430989
[TBL] [Abstract][Full Text] [Related]
15. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I; Lieb K
CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of NK1R attenuates LPS-induced microglial inflammation and consequent death of PC12 cells.
Jiang W; Wang X; Wang W; Hua F; Zhang Z; Zhang Z; Xiang J; Yang X
Brain Res Bull; 2020 Sep; 162():115-124. PubMed ID: 32540418
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
[TBL] [Abstract][Full Text] [Related]
18. Cellular and behavioral effects of lipopolysaccharide treatment are dependent upon neurokinin-1 receptor activation.
Fulenwider HD; Smith BM; Nichenko AS; Carpenter JM; Nennig SE; Cheng K; Rice KC; Schank JR
J Neuroinflammation; 2018 Feb; 15(1):60. PubMed ID: 29486768
[TBL] [Abstract][Full Text] [Related]
19. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
20. Possible ligand-receptor interactions for NK1 antagonists as observed in their crystal structures.
Boks GJ; Tollenaere JP; Kroon J
Bioorg Med Chem; 1997 Mar; 5(3):535-47. PubMed ID: 9113332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
